Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01979887 · ClinicalTrials.gov registry record
Characterization of Signs and Symptoms of Participants With and Without Meibomian Gland Dysfunction
A clinical trial of Meibomian Glands, sponsored by Allergan.
- Completed
- Registry status
- 75
- Enrollment target
- 2
- Study locations
NCT01979887 is a study of Meibomian Glands that has completed, run by Allergan. The registered enrollment target is 75 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT01979887, a study of Meibomian Glands, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 75 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an exploratory study to evaluate endpoints used to characterize participants with and without meibomian gland dysfunction (MGD) and will evaluate the correlation between signs and symptoms of MGD. No investigational drug will be administered in this study.
Conditions Studied
Interventions
- PROCEDURE Meibum Expression
Study Locations (2)
Texas
- - Houston
Other
- - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01979887
The ClinicalTrials.gov registry entry for NCT01979887 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Meibomian Glands appearing as the primary indexed condition, and to 1 intervention - of which Meibum Expression is the first listed.
NCT01979887 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Other.
Frequently Asked Questions
What is clinical trial NCT01979887 about?
NCT01979887 is a clinical study titled "Characterization of Signs and Symptoms of Participants With and Without Meibomian Gland Dysfunction". This is an exploratory study to evaluate endpoints used to characterize participants with and without meibomian gland dysfunction (MGD) and will evaluate the correlation between signs and symptoms of MGD. No investigational drug will be administered in this study.
What is the current status of trial NCT01979887?
This trial is currently completed. The enrollment target is 75 participants. The study started on 2013-11. Estimated completion is 2014-07.
What conditions does trial NCT01979887 study?
This clinical trial studies the following conditions: Meibomian Glands.
What interventions are being tested in trial NCT01979887?
The interventions under investigation include: Meibum Expression (PROCEDURE).
Who is sponsoring clinical trial NCT01979887?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01979887 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.